Analyzing...
Loading company...
Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-06-29. The Company’s manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals and nutrients (VMN). The firm's brands include Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Company’s wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited and Eris Healthcare Private Limited.
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹3,129 Cr revenue.
COGS 25.4%, employees 17.8%.
“market opportunity can be more than a billion dollars.”
“basis h one run rate, we have a visibility of 12 12% revenue growth for this year of year of year of year, which we build and we exceed of 15%.”
“CapEx outlay over the next three quarters to be at around $3.”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 15.9%▲ | 10.3% |
| ROCE | 15.7%▲ | 13.7% |
| Net Margin | 19.8%▲ | 7.6% |
| EBITDA Margin | 35.4%▲ | 15.4% |
| Debt To Equity | 0.59x▲ | 0.15x |
| Rev Growth 3yr | 22.8%▲ | 10.0% |
| EPS Growth 3yr | 16.8%▲ | 16.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,129 Cr +8.1% | ₹2,894 Cr +44.0% | ₹2,009 Cr +19.2% | ₹1,685 Cr +25.1% | ₹1,347 Cr +11.2% | ₹1,212 Cr +12.8% | ₹1,074 Cr +9.4% | ₹982 Cr |
| Other Income | ₹8 Cr -57.8% | ₹18 Cr -22.9% | ₹24 Cr +113.5% | ₹11 Cr -57.3% | ₹26 Cr +199.7% | ₹9 Cr -43.4% | ₹15 Cr -51.4% | ₹32 Cr |
| Total Income | ₹3,137 Cr +7.7% | ₹2,912 Cr +43.2% | ₹2,033 Cr +19.8% | ₹1,696 Cr +23.5% | ₹1,373 Cr +12.5% | ₹1,221 Cr +12.0% | ₹1,089 Cr +7.5% | ₹1,014 Cr |
| COGS | ₹796 Cr +11.4% | ₹714 Cr +87.9% | ₹380 Cr +7.9% | ₹352 Cr +36.3% | ₹259 Cr +8.5% | ₹238 Cr +38.9% | ₹172 Cr +11.6% | ₹154 Cr |
| ₹2,481 Cr +2.4% | ₹2,423 Cr +51.3% | ₹1,602 Cr +24.0% | ₹1,292 Cr +38.7% | ₹931 Cr +12.7% | ₹826 Cr +9.0% | ₹758 Cr +8.8% | ₹696 Cr | |
| Profit Before Tax | ₹638 Cr +30.6% | ₹489 Cr +13.4% | ₹431 Cr +6.6% | ₹405 Cr -8.5% | ₹442 Cr +12.1% | ₹394 Cr +19.1% | ₹331 Cr +4.4% | ₹317 Cr |
| Exceptional Items | (₹17 Cr) | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
| (₹9 Cr) ↓ Decline | ₹114 Cr +234.1% | ₹34 Cr +12.1% | ₹30 Cr -16.3% | ₹36 Cr -7.5% | ₹39 Cr +13.0% | ₹35 Cr +32.9% | ₹26 Cr | |
| Net Profit | ₹648 Cr +72.8% | ₹375 Cr -5.6% | ₹397 Cr +6.1% | ₹374 Cr -7.8% | ₹406 Cr +14.3% | ₹355 Cr +19.8% | ₹297 Cr +1.8% | ₹291 Cr |
| Profit (Owners) | ₹620 Cr +76.1% | ₹352 Cr -10.2% | ₹392 Cr +2.6% | ₹382 Cr -5.9% | ₹406 Cr +14.4% | ₹355 Cr +19.8% | ₹297 Cr +2.0% | ₹291 Cr |
| Minority Interest | ₹28 Cr +22.6% | ₹23 Cr +350.2% | ₹5 Cr ↑ Recovery | (₹8 Cr) | (₹0.32 Cr) | ₹0.00 Cr | ₹0.00 Cr -100.0% | ₹0.35 Cr |
| Other Comprehensive Income | (₹1 Cr) +56.2% | (₹3 Cr) -7.8% | (₹3 Cr) ↓ Decline | ₹0.06 Cr ↑ Recovery | (₹0.98 Cr) +34.0% | (₹1 Cr) -22.2% | (₹1 Cr) -977.9% | (₹0.11 Cr) |
| EPS | ₹45.13 | ₹25.84 | ₹28.82 | ₹28.10 | ₹29.88 | ₹26.16 | ₹21.84 | ₹21.15 |
| Diluted Shares | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr |
| Profit Or Loss Of Associates | ₹0.09 Cr +50.0% | ₹0.06 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr | ₹0.00 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Eris Lifesciences Limited has informed the Exchange about Schedule of meet
Eris Lifesciences Limited has informed the Exchange regarding Allotment of 4816 Shares.
Eris Lifesciences Limited has informed the Exchange about Link of Recording
Eris Lifesciences Limited has informed the Exchange about Investor Presentation
Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended June 30, 2026.
Eris Lifesciences Limited has informed the Exchange about Schedule of meet
Eris Lifesciences Limited has informed the Exchange regarding 'payment made of theinterest to the holders of Non-convertible Debentures'.
Eris Lifesciences Limited has informed the Exchange about Action(s) taken or orders passed
Eris Lifesciences Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regu...
Eris Lifesciences Limited has informed the Exchange about Schedule of meet
Eris Lifesciences Limited has informed the Exchange about Investor Presentation
Eris Lifesciences Limited has informed the Exchange that Record date for the purpose of Dividend is 29-May-2026.
Eris Lifesciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
Eris Lifesciences Limited has informed the Exchange about Schedule of meet
Eris Lifesciences Limited has informed the Exchange regarding Allotment of 24369 Shares.